focus -WSS

focus

author：Wikipedia 2025-08-28 08:41:05 - browse：1641

Kidney transplants are the most common organ transplant procedure in the U.S., with 25,000 taking place in 2022. But for patients who receive new kidneys, the transplant is often followed by severe lifelong challenges, many of which are linked to the immunosuppression drug regimen required after surgery to ensure the body does not reject the new organ. These treatments have side effects and toxicities that impact patients’ long-term health, and even survival, leading to a transplant failure rate of 30-50% at the 10-year mark.

Now a new trial sponsored by Medeor Therapeutics, the results of which were presented Thursday at the American Society of Nephrology (ASN) Kidney Week 2023 Annual Meeting, offers hope that stem cell therapy may help patients discontinue their immunosuppressant regime within a year of the transplant.

“The ability to get a transplant without being on lifelong immunosuppression is kind of a dream in transplant, so I can see why this would generate a lot of excitement,” said Sommer Gentry, a professor of surgery at New York University, who was not involved in the study and was not at the actual presentation, but reviewed the trial’s presentation slides.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

WSS

Copay coupons to count toward deductibles, after Biden court move

Medicare Advantage today, explained in one chart

Copay coupons to count toward deductibles, after Biden court move

Emergency medicine has repudiated 'excited delirium.' Now what?

Medtronic CEO on promising devices for diabetes, hypertension

Paying for Covid pills will soon shift to insurers

leisure time

focus

focus

Dobbs anniversary: the lost opportunity of abortion as health care

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

Bright Health sells Medicare Advantage business to Molina

Readout Newsletter: XBI biotech index, Akero Therapeutics

How one medical school became remarkably diverse

Research misconduct: Proposed new rules face resistance

Cancer drug shortages should be causing more outrage

Dewpoint Therapeutics lays off staff after losing partnerships

In Memoriam: Notable people who died in 2023

Readout Newsletter: XBI biotech index, Akero Therapeutics

hotspot

Emergency medicine has repudiated 'excited delirium.' Now what?

Physician subsidies by hospitals soar in wake of No Surprises Act

EU regulator recommends expanding Mounjaro approval to obesity

Cassava reveals details — and problems — with Alzheimer's study

The FDA weighs the risks of candy

The FDA weighs the risks of candy

leisure time

explore

hotspot

knowledge